Drug Information

Drug General Information
Drug ID
D05CVC
Former ID
DIB004951
Drug Name
90Y-cG250
Synonyms
Radiolabeled G250 derived mAb (cancer), Wilex/Ludwig Institute; 90Y-DOTA-cG250
Drug Type
Antibody
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1 [521704]
Company
Wilex AG
Target and Pathway
Target(s) Carbonic anhydrase IX Target Info [532393]
KEGG Pathway Nitrogen metabolism
Pathway Interaction Database HIF-1-alpha transcription factor network
Reactome Regulation of gene expression by Hypoxia-inducible Factor
Reversible hydration of carbon dioxide
WikiPathways Vitamin D Receptor Pathway
Reversible Hydration of Carbon Dioxide
Regulation of Hypoxia-inducible Factor (HIF) by Oxygen
References
Ref 521704ClinicalTrials.gov (NCT00199875) Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250. U.S. National Institutes of Health.
Ref 532393Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.